Open Label Study to Assess the Effect of Secukinumab in Moderate to Severe Papulopustular Rosacea

Anne Chang

Status and phase: Completed; Phase 2; Phase 1

Conditions: Papulopustular Rosacea

Treatments: Drug: Secukinumab

Study type: Interventional

Funder types: Other

Identifiers

NCT03079531

e-protocol 38599

Details and patient eligibility

About

This is a study to determine whether secukinumab is a potential therapy for those with papulopustular rosacea. We will observe whether this drug decreases the size and/or amount and severity of the pustules of those who suffer from rosacea.

Full description

Rosacea is a common inflammatory skin disease affecting up to 10% of adults. Despite this, the etiology of rosacea is unclear, although there may be a genetic predisposition (Chang et al., 2015). Currently, there is no cure. Rosacea can lead to scarring, itching, burning, and is associated with anxiety and depression (Moustafa et al., 2015), significantly affecting quality of life.

Secukinumab is an antibody that binds to a protein (interleukin (IL)-17A) that is involved in inflammation. When IL-17A is bound to secukinumab, it cannot bind to its receptor, thereby inhibiting its ability to feed the inflammatory response. In clinical trials, secukinumab has been effective for moderate to severe psoriasis (Blauvelt et al., 2015). Recently, human data from all types of rosacea have shown Th1/Th17 polarization profile of the T-cell response, suggesting that anti-IL-17 therapy may be beneficial for rosacea (Buhl et al., 2015). Hence, secukinumab could be effective against rosacea. This proposal is a proof-of-concept study to use secukinumab in open label design for moderate to severe papulopustular rosacea.

Enrollment: 24 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• moderate to severe papulopustular rosacea defined clinically using the grading system of Wilkin et al. (2004) as having at least ten lesions (either papules or pustules) on face at time of enrollment
• age 18 years or greater willing and able to understand and sign informed consent form

Exclusion criteria

• known hypersensitivity to secukinumab
• topical or oral anti-rosacea medication usage for 28 days prior to enrollment
• active Crohn's disease, as secukinumab may exacerbate this disease
• active infection including tuberculosis, hepatitis B or C, human immunodeficiency virus
• participants with latent tuberculosis will need to have treatment initiated prior to starting study drug
• pregnant or lactating
• active and/or uncontrolled medical conditions that may interfere with study procedures or obscure rosacea assessment such as cutaneous lupus
• use of retinoids within past 3 months of enrollment
• use of antibiotics within 4 weeks of enrollment
• use of light based or laser treatment to face within 8 weeks of enrollment
• use of topical or systemic steroids within 4 weeks of enrollment
• acne conglobate, acne fulminans, chloracne, severe acne requiring systemic treatment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

24 participants in 1 patient group

Secukinumab arm

Experimental group

Description:

Participants receive secukinumab (7 doses over a 16-week study period).

Treatment:

Drug: Secukinumab

Sponsor of this trial

Lead Sponsor

Anne Chang